Clinical Trial Update: Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating romiplostim for immune thrombocytopenic purpura (ITP) has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Amgen | Conditions: Idiopathic Thrombocytopenic Purpura | Phase 2 | Status: COMPLETED | Results posted: 2020-01-10